Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Abstract Background There is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus exemestane in patients with metastatic HR+ HER2− breast cancer previou...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2021-01-01
|
| Seri Bilgileri: | Breast Cancer Research |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s13058-021-01394-y |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|